Hong Kong’s Regencell Bioscience triples in latest surge for a speculative stock

REGENCELL BİOSCİCience HoldingsAn early stage without income, a Hong Kong -based Bioscience company, the latest speculative overseas stock to attract an unusual increase in trade demand.

After three floors of three floors on Monday, Regelencell shares say that he developed traditional Chinese plant treatments to treat care deficit hyperactivity disorder and autism in childhood – 38-1-Split It was announced on June 2. According to S&P Capital IQ, Regelencell, which was founded in 2014 and traded under the ‘RGC’ since 2021 in Nasdaq, has been traded under the ‘RGC’ Ticket ‘RGC’ since 2021.

The stock continued to jump on Tuesday and won 30%. The company’s performance has increased by 59,900% in 2025. Stocks have been traded for Pennies at one point in the last year.

Regencell is the last example of a speculative international stock that attracts attention during summer trade. For example, in August 2022, AMTD DigitalA Fintech company based on Hong Kong climbed 126%and briefly gave him a larger market value. Coca And Bank of America.

At the beginning of this month, the regencell stock division was designed only to “increase liquidity in the market for the usual shares of the company and make stocks more accessible to investors”. Stock divisions do not basically change anything about a company.

Regenccell’s fluctuation came in the midst of focusing on alternative drugs after Robert F. Kennedy Jr. Kennedy, a vaccine skeptic, took steps to deterd the routine vaccines in the United States and removed all members of a panel that recommended disease control and prevention centers on vaccines last week.

Regencell’s shares often make a large -day swings. For example, stocks increased approximately 30% on March 21 before decreasing 30% to the next trading day.

Uncertain treatments, zero income

Despite the wild Virgo in stock, very little is known about the effectiveness and commercialization of Regell’s treatment for ADHD and autistic spectrum disorders.

Regenccell’s business centers, business centers on a registered traditional Chinese medical formula (TCM) developed jointly with TCM practitioner Sik-Kake Au “Sik-Kee AU TCM brain theory.“Fuck-kee au The father of the President of the Regenccell Executive Board Yat Yat-Gai Au said in the company’s 2022 statement.

According to Factset data, CEO controls 86.24% of the total number of shares.

Three liquid -based, orally taken TCM formulas candidates It contains natural components such as alleged to address light, moderate and severe conditions and only “detoxication plants”, blood circulation herbs and digestive herbs.

“This is the basis of our TCM product candidates, which we plan to develop and commercialize TCM formulas, ADHD and ASD treatment.”

Inside Last year’s report last OctoberRegenccell said it did not generate any income or that TCM formulas were not opened for regulatory approval. According to a filing of the SEC, Regenccell, which ended in 2024 and 2023 June and 2023, has caused total net damages of $ 4,36 million and $ 6.06 million, respectively net damages for total net damages.

“We did not earn income from any TCM formula candidate or applied for any regulatory approval, we do not have distribution capabilities or experiences or patents or waiting patent applications and can never be profitable.”

Regencell did not respond to a CNBC comment request.

REGENCELL Latest patient case studyDated November 15, 2023, according to the company’s web page, 28 patients were given treatment for three months in a second activity study and showed an improvement in ADHD and ASD symptoms.

In an earlier case, Regencell said in 2021. newsletter AU’s modified-registered cold and flu tcm formula using a modified version of a dozen patients with a suspicious or verified COVID-19 cases. What is defined as the improvement of Covid conditions led Regelencell to establish a joint venture with Honor Epic Enterprises Limited in September 2021, and the Company’s joint venture to commercialize COVID treatment in the Southeastern Asian Nations Association.

Online Buzz

The stock spoke very little on social media for the last few years. These comments propose both the enthusiasm of the trader and the skepticism.

A user on Reddit page “R/ShortSqueeze” On Monday, Regencell wrote that he was doing a breast coin. He bought a little to see what happened and fell 50% immediately after LoL. ” Another user in an article made three months ago, “I am confusing the RGC for some snow.” The stock increased only 1.360% in May.

An investor said in LinkedIn in May “I can’t stop laughing“After reading the company statement. A user in the pharmaceutical industryAccording to his profile, Regelencell said in May that he was “shares to watch” after the spike in “No official news or catalysts”. Last month, another LinkedIn user, “China -based, low volume and official news, Bizarro,” he commented on Regeencell.

In X, a user wrote in Monday, ” #Completebullshcompanyoftheear I nominate Regencell. “

– Scott Schnipper from CNBC contributed to reporting.